Ironwood’s Phase III Data Could Expand Linzess Market Share

 
• By Alaric DeArment

The company also hopes that positive safety data for pediatric patients could help with discussions with the FDA to make an OTC version of the drug.

Phase III pediatric data could expand market share for Ironwood's Linzess • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas